Aakaar Medical

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 24-Aug, Aakaar Medical Technologies Ltd's stock price is rising to 62.00, supported by a 22.65% gain over the past week and increased investor participation. The stock is currently outperforming its sector and shows a positive short-term trend, despite being below longer-term moving averages.

As of 24-Aug, Aakaar Medical Technologies Ltd's stock price is rising, currently at 62.00, with an increase of 0.7 (1.14%). This upward movement is supported by a significant performance over the past week, where the stock has outperformed the benchmark Sensex, showing a remarkable gain of 22.65% compared to the Sensex's decline of 0.28%. Additionally, today's performance indicates that the stock has outperformed its sector by 1.23%. <BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume of 17.6k on 21 August, which is up by 3.77% against the 5-day average delivery volume. This suggests growing interest and confidence among investors. Furthermore, the stock is currently trading higher than its 5-day and 20-day moving averages, indicating a short-term positive trend, although it remains below the longer-term moving averages of 50-day, 100-day, and 200-day. <BR><BR>Overall, the combination of strong recent performance, increased investor participation, and positive short-term moving averages contributes to the rising stock price of Aakaar Medical Technologies Ltd.

Which are the latest news on Aakaar Medical?

What does Aakaar Medical do?

Aakaar Medical Technologies Ltd is a micro-cap company in the healthcare services industry with no reported sales or profits. It has a market cap of INR 79 Cr, a P/E ratio of 11.00, and a debt-equity ratio of 0.04.

Overview: <BR>Aakaar Medical Technologies Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>There are no details available regarding the incorporation year or any status changes. Additionally, no sales or profit data has been reported for any quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 79 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity (ROE): 12.17% <BR>Price-to-Book: 1.46 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aakaar Medical?

Aakaar Medical's peers include Bilcare, Choksi Laborator, Shree Pacetronix, Aspira Pathlab, Royal Sense, KMS Medisurgi, and Amkay Products. Aakaar Medical has good management risk and growth, but its 1-year return is the lowest among peers at -39.10%, despite a positive six-month return of 11.15%.

Peers: The peers of Aakaar Medical are Bilcare, Choksi Laborator, Shree Pacetronix, Aspira Pathlab, Royal Sense, KMS Medisurgi, and Amkay Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shree Pacetronix, Royal Sense, and Amkay Products, while Good management risk is found at Aakaar Medical. Below Average management risk is noted at Bilcare, Choksi Laborator, and Aspira Pathlab, and Average management risk is present at KMS Medisurgi. Growth is Excellent at Royal Sense, Good at Aakaar Medical, Shree Pacetronix, and Choksi Laborator, while Below Average growth is seen at Bilcare, Aspira Pathlab, and KMS Medisurgi, and the rest have Average growth. Capital Structure is Good at Aakaar Medical, Shree Pacetronix, Royal Sense, and Amkay Products, while Below Average is noted at Bilcare and Choksi Laborator, and Average at Aspira Pathlab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMS Medisurgi at 0.00%, while Aakaar Medical has the lowest at -39.10%, indicating a significantly poorer performance compared to its peers. Additionally, Aakaar Medical's six-month return is positive at 11.15%, while all other peers report a six-month return of 0.00%.

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.